CompletedNot Applicable

Clinical-pathological Characterization and Outcomes of Metastatic Urothelial Cancer in Latin America

Brazil218 participantsStarted 2019-08-01

Plain-language summary

The LACOG 1518 study will characterize demographic and clinical-pathological profile of patients diagnosed with recurrent/ metastatic urothelial cancer in Latin America.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age at least 18 years;
✓. Histological confirmation of urothelial carcinoma (include mixed urothelial histology);
✓. Diagnosis of recurrent or metastatic (Stage IV) urothelial carcinoma during the period of January 2016 to July 2018;
✓. Site and investigator ability to collect adequate patient characteristics, treatment and outcome data from medical records;
✓. Availability of tumor sample (FFPE/slides) from primary tumor or metastatic site at the time of registration.

Exclusion criteria

✕. Synchronous tumors or history of other malignancy in the previous 3 years before study entry (exception to non-melanoma skin cancer or non-invasive cancers);
✕. Pure non-urothelial carcinoma histology.

What they're measuring

Epidemiology

Timeframe: 2 years

Trial details

NCT IDNCT03942497

SponsorLatin American Cooperative Oncology Group

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2021-08-31

View on ClinicalTrials.gov More Recurrent/Metastatic Urothelial Cancers trials